Combination Therapy Prevents the Relapse of RA

• Status: Recruiting
• Trial end date: 2020-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This trial aims to compare the cost effective and effect of preventing recurrence by different treatment of TFP and HCQ combined SSZ for remittent RA.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Peking University First Hospital
• Collaborators: Beijing Hospital; Beijing Jishuitan Hospital; Beijing Shijitan Hospital; Beijing Shijitan Hospital, Capital Medical University; Peking University People's Hospital; Peking University Shougang Hospital; Peking University Third Hospital

Criteria

Inclusion Criteria:

• Fulfill 2010 EULAR/ACR RA dignose criteria

• Age18-70 years old

• Have been teated regularly for 3 months

• Disease duration > 6months

• DAS28>3.2

Exclusion Criteria:

• Received surgical operation in 8 weeks

• Received other biological agent (eg. rituximab, anti-TNF agents, anti-IL6 agents)in 6 months;

• Injection of steroid in 4 weeks

• Coexisting with other CTD except for SS

• With severe and not controled cardiac vescular disease, neurological disease, pulmonary disease (including COPD and ILD), renal disease, liver disease, endocrine disease and Gastric Intestinal Disease

• With not controled diseases including asthma, IBD and psoriasis needing oral or injection of steroid

• Active infection with T>38℃. Patients need admitted into hospital or biotics injection in 4 weeks or need oral biotics in 2 weeks

• Malignant history.

• Serum creatinine >130 µmol/L

• AST/ALT higher than 2 times upper level

• platelet count<100 x 109/L，or white blood count<3 x 109/L

• Interstitail lung disease: Chest X Ray

• Hands X Ray ACR radiology staging shows IV stage RA

• Pregnancy or planing to pregnant in 2 years or suckling period women.